Laboratorios Farmaceuticos Rovi Statistics
Want to see ES:ROVI full AI Analyst Report?
Laboratorios Farmaceuticos Rovi (ROVI) Stock Statistics & Valuation Metrics
Total Valuation
Laboratorios Farmaceuticos Rovi has a market cap or net worth of EUR 3.52B. The enterprise value is EUR 3.06B.
- Market Cap
- EUR 3.52B
- Enterprise Value
- EUR 3.06B
Share Statistics
Laboratorios Farmaceuticos Rovi has 51,235,764 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 51,235,764
- Owned by Insiders
- ―
- Owned by Institutions
- 5.29%
Financial Efficiency
Laboratorios Farmaceuticos Rovi’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 16.52%.
- Return on Equity (ROE)
- 0.21
- Return on Assets (ROA)
- 0.15
- Return on Invested Capital (ROIC)
- 16.52%
- Return on Capital Employed (ROCE)
- 0.22
- Revenue Per Employee
- 333.10K
- Profits Per Employee
- 62.92K
- Employee Count
- 2,232
- Asset Turnover
- 0.78
- Inventory Turnover
- 1.01
Valuation Ratios
The current PE Ratio of Laboratorios Farmaceuticos Rovi is 17.04. Laboratorios Farmaceuticos Rovi’s PEG ratio is 2.04.
- PE Ratio
- 17.04
- PS Ratio
- 4.23
- PB Ratio
- 4.49
- Price to FCF
- 29.49
- Price to Operating Cash Flow
- 17.87
- PEG Ratio
- 2.04
Income Statement
In the last 12 months, Laboratorios Farmaceuticos Rovi had revenue of 743.48M and earned 140.44M in profits. Earnings per share was 2.75.
- Revenue
- 743.48M
- Gross Profit
- 451.65M
- Operating Income
- 173.14M
- Pretax Income
- 183.26M
- Net Income
- 140.44M
- EBITDA
- 203.52M
- Earnings Per Share (EPS)
- 2.75
Cash Flow
In the last 12 months, operating cash flow was 196.09M and capital expenditures -77.29M, giving a free cash flow of 118.80M billion.
- Operating Cash Flow
- 196.09M
- Free Cash Flow
- 118.80M
- Free Cash Flow per Share
- 2.32
Dividends & Yields
Laboratorios Farmaceuticos Rovi pays an annual dividend of EUR 0.96, resulting in a dividend yield of 1.38%
- Dividend Per Share
- EUR 0.96
- Dividend Yield
- 1.38%
- Payout Ratio
- 26.51%
- Free Cash Flow Yield
- 3.39%
- Earnings Yield
- 5.87%
Stock Price Statistics
- Beta
- 0.59
- 52-Week Price Change
- 17.50%
- 50-Day Moving Average
- 60.60
- 200-Day Moving Average
- 65.42
- Relative Strength Index (RSI)
- 73.19
- Average Volume (3m)
- 106.02K
Important Dates
Laboratorios Farmaceuticos Rovi upcoming earnings date is Feb 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 24, 2027
- Ex-Dividend Date
- Jul 13, 2026
Financial Position
Laboratorios Farmaceuticos Rovi as a current ratio of 3.14, with Debt / Equity ratio of 18.32%
- Current Ratio
- 3.14
- Quick Ratio
- 1.55
- Debt to Market Cap
- 0.03
- Net Debt to EBITDA
- 0.12
- Interest Coverage Ratio
- 60.84
Taxes
In the past 12 months, Laboratorios Farmaceuticos Rovi has paid 42.90M in taxes.
- Income Tax
- 42.90M
- Effective Tax Rate
- 0.23
Enterprise Valuation
Laboratorios Farmaceuticos Rovi EV to EBITDA ratio is 12.76, with an EV/FCF ratio of 29.74.
- EV to Sales
- 4.26
- EV to EBITDA
- 12.76
- EV to Free Cash Flow
- 29.74
- EV to Operating Cash Flow
- 18.02
Balance Sheet
Laboratorios Farmaceuticos Rovi has EUR 70.92M in cash and marketable securities with EUR 100.95M in debt, giving a net cash position of -EUR 30.03M billion.
- Cash & Marketable Securities
- EUR 70.92M
- Total Debt
- EUR 100.95M
- Net Cash
- -EUR 30.03M
- Net Cash Per Share
- -EUR 0.59
- Tangible Book Value Per Share
- EUR 14.92
Margins
Gross margin is 64.38%, with operating margin of 21.51%, and net profit margin of 24.81%.
- Gross Margin
- 64.38%
- Operating Margin
- 21.51%
- Pretax Margin
- 30.75%
- Net Profit Margin
- 24.81%
- EBITDA Margin
- 33.41%
- EBIT Margin
- 29.06%
Analyst Forecast
The average price target for Laboratorios Farmaceuticos Rovi is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 14.41%
- EPS Growth Forecast
- 69.69%
Scores
- Smart Score
- 4
- AI Score
- 76

